Key result
Precise oral glucose and insulin loading yields ~89% high-quality PET images in diabetic CAD.
Why the study?
The feasibility of a precise oral glucose loading combined with subcutaneous insulin protocol for 18F-FDG PET myocardial metabolic imaging in CAD patients with diabetes mellitus was evaluated.
Does a precise oral glucose loading combined with subcutaneous insulin administration protocol yield feasible and high-quality 18F-FDG PET myocardial metabolic imaging in CAD patients with diabetes mellitus?
Cohort (n=179)
No
Does a precise oral glucose loading combined with subcutaneous insulin administration protocol yield feasible and high-quality 18F-FDG PET myocardial metabolic imaging in CAD patients with diabetes mellitus?
A precise oral glucose loading and subcutaneous insulin protocol is safe and yields good-to-excellent 18F-FDG PET image quality in over 97% of diabetic patients with CAD.
Protocol feasible for FDG-PET in CAD with DM; hypothesis-generating and requires prospective validation before clinical adoption.
Objectives We evaluated the feasibility of using a precise oral glucose loading combined with subcutaneous insulin administration protocol for 18 F-FDG PET myocardial metabolic imaging in patients with coronary artery disease (CAD) complicated by diabetes mellitus (DM). Methods 179 consecutive CAD patients complicated by DM were enrolled. Oral glucose was given at variable doses based on baseline blood glucose, and subcutaneous insulin was injected at adjusted doses according to post-load glucose levels before FDG injection. SPECT myocardial perfusion imaging and PET myocardial metabolic imaging were performed using a one-day protocol. The image quality and adverse reaction data were analyzed. Results Among 179 patients, FDG image quality was scored as excellent in 57.5%, very good in 31.8%, good in 7.8%, fair in 1.7% and non-diagnostic in 1.1%. When patients were stratified by blood glucose level at time of FDG injection >7.77 mmol/L, 5.55–7.77 mmol/L and <5.55 mmol/L, the image quality were excellent in 43.1, 60.4 and 74.1%, very good in 43.1, 30.7 and 14.8%, good in 9.8, 5.9 and 11.1%, fair in 3.9, 1.0% and 0, and non-diagnostic in 0, 2.0% and 0, respectively. Patients were divided into insulin therapy group and oral medication group, the image quality were excellent in 50.7 and 62.5%, very good in 33.3 and 30.8%, good in 10.7 and 5.8%, fair in 2.7 and 1.0%, and non-diagnostic in 2.7% and 0, respectively. Patients with blood glucose at time of FDG injection >7.77 mmol/L had significantly lower odds of excellent image quality ( p = 0.021) than those with 5.55–7.77 mmol/L or <5.55 mmol/L, while no significant difference was observed between the latter two groups ( p = 0.262). 47 patients (26.3%) exhibited completely viable myocardium, 89 patients (49.7%) had partially viable myocardium, and 43 patients (24.0%) showed nonviable myocardium. None of the patients had severe adverse reactions. Conclusion The precise oral glucose loading protocol prior to 18 F-FDG injection is feasible for clinical application.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) conducted a cohort in Coronary artery disease complicated by diabetes mellitus (n=179). Precise oral glucose loading combined with subcutaneous insulin administration was evaluated on Excellent 18F-FDG PET image quality. A precise oral glucose loading combined with subcutaneous insulin administration protocol yielded excellent or very good diagnostic image quality in 89.3% of patients with coronary artery disease complicated by diabetes mellitus, with no severe adverse reactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: